PEPTOKING
EN

Review of 565 studies finds little human evidence for popular injectable peptides

Research

UCLA researchers reviewed 565 studies of six compounds marketed for recovery and performance: BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and the non-peptide MK-677. More than two-thirds of the studies were in animals only, and the few human studies were small, poorly controlled and showed modest benefits at best. Published in The American Journal of Sports Medicine, the review also flagged safety concerns, including heart failure risk seen with MK-677 and possible contamination of unregulated products.

Sources

  1. 01Peptide Supplements and Their Therapeutic Applications in Sports Medicine(opens the source in a new tab) The American Journal of Sports Medicine
  2. 02With peptide supplements, marketing outpaces the medicine(opens the source in a new tab) UCLA Newsroom

Peptides involved

  1. Not approvedBPC-157Synthetic gastric pentadecapeptide (research chemical)15 WADA banned
  2. Not approvedTB-500Thymosin beta-4 fragment (research chemical)7 WADA banned
  3. Not approvedCJC-1295Long-acting GHRH analogue (research peptide)30 WADA banned
  4. Not approvedIpamorelinGrowth hormone secretagogue (ghrelin receptor agonist)5 WADA banned
  5. Cosmetic ingredientGHK-CuCopper-binding tripeptide (cosmetic ingredient)3